Reni M, et al. - Experts evaluated if, for borderline and locally advanced pancreatic adenocarcinoma (PDAC), the addition of cisplatin and capecitabine to the nab-paclitaxel–gemcitabine backbone is feasible and effective. Fifty-four chemo-naïve adult patients with a diagnosis of locally advanced or borderline resectable PDAC were given either nab-paclitaxel, gemcitabine, cisplatin and oral capecitabine or nab-paclitaxel followed by gemcitabine. Findings of this phase 2 study suggested the feasibility of the addition of cisplatin and capecitabine to the gemcitabine (AG) backbone. In terms of disease control, the results were promising with this treatment strategy, and no negative impact on tolerability was seen.